AlloSure as a Tool for Surveillance of Renal Transplant Patients: Real World Evidence and Clinical Utility
The CareDx Exhibitor Spotlight will cover a variety of topics regarding the value of AlloSure for the surveillance of post-kidney transplant patients, including: Dr. Peev presenting Clinical Utility of Kidney Transplant Surveillance with AlloSure, Dr. Anand presenting Baseline Characteristics and Relative Change Value of AlloSure, Dr. Alhamad presenting AlloSure as a Predictor of Clinical Outcomes, Dr. Ali presenting COVID-19 and Renal Transplantation: The NYU Experience, and Dr. Mahale presenting AlloSure Experience in the Community.
Tarek Alhamad, MD, MS, FACP, FASN Barnes Jewish Washington University Transplant Center
Tarek Alhamad, MD, MS, FACP, FASN, Associate Professor of Nephrology, Medical Director of Kidney and Pancreas Transplant Programs at Barnes Jewish Washington University Transplant Center. Dr. Alhamad received his MD from Damascus University and a Master Degree in Public Health Science at the Pennsylvania State University where he also completed his nephrology fellowship. He completed his medical internship and residency at the Texas Tech University and did further training in Transplant Nephrology at Mayo Clinic.
Dr. Alhamad's research interests are outcome research in kidney and pancreas transplant. He has more than 50 publications and book chapters. He is one of the Editor of Washington Manual in Nephrology. He is the Director of Transplant Epidemiology Research Collaboration at the Institute of Public Health and the Director of the Annual Midwest Transplant Symposium.
Dr. Alhamad was elected in 2017 to serve on the Executive Committee of the Kidney and Pancreas Community of Practice (KPCOP.) He served in the Education Committee of the American Society of Transplantation (AST) from 2016 to 2019. He was recently appointed as Region 8 representative to the United Network Organ Sharing (UNOS) pancreas committee for a 3 year term.
Nicole M. Ali, MD New York University School of Medicine
Dr. Nicole M. Ali is an assistant professor of medicine at the New York University School of Medicine, Medical Director of kidney and pancreas transplantation, and Director of Outreach. Following completion of her undergraduate degree at Brown University she joined the Americorp Program, Teach for America. She earned her Medical degree from SUNY - Stony Brook. She is board certified in Internal Medicine and Nephrology and is an AST/ASN certified transplant nephrologist, trained at Columbia University Medical Center, NY.
She has held positions as the Chief of Transplantation at Hackensack University Medical Center for the kidney and pancreas transplant programs and the Medical Director of the kidney transplant program at North Shore University Hospital. She has extensive experience working with programs that experienced outcome issues including system improvement agreements and structuring transplant quality programs. She has published many articles in peer reviewed journals and presents lectures locally and internationally. Her current areas of research include increasing access to transplantation, improving organ utilization and novel desensitization strategies.
Sanjiv Anand, MD Intermountain Medical Center
Dr. Sanjiv Anand, MD, is a board-certified transplant nephrologist and currently serves as the director of Living Donor Program and Clinical Research at Intermountain Medical Center, in Salt Lake City, Utah. Dr Anand completed his residency in internal medicine from Maimonides Medical Center, NY, and nephrology fellowship from Indiana University, Indianapolis. Subsequently, Dr. Anand completed a transplant nephrology fellowship at Indiana University, Indianapolis. He currently serves as a principal investigator for over fifteen studies- including both chronic kidney disease and kidney transplant. His research interests include biomarkers for kidney transplant rejection, denovo and complement mediated glomerulonephritis in transplant kidney recipients and increasing access to kidney transplant via process improvement and use of technology. He also serves on advisory boards for industry partners, and has been an ad hoc reviewer for peer-reviewed transplant journals.
Adit S. Mahale, MD Metrolina Nephrology Associates
My name is Adit S Mahale. I graduated from the University of Mumbai in 1997. I did my Internal Medicine residency and Nephrology Fellowship from the University of Missouri in Columbia. I then completed my Transplant Nephrology fellowship from the Mayo Clinic in Rochester, MN. I was the Medical Director of the Kidney and Pancreas Transplant at the Sanford Hospital in Fargo, ND between 2004-18. I joined Metrolina Nephrology Associates in Charlotte, NC in July 2018. We are a large Nephrology group of 35 Nephrologists and 30 advanced practitioners. I am currently affiliated with the Atrium Health Medical System in Charlotte. We do about 150 kidney transplants at our center every year.
I am passionate about caring for kidney and pancreas transplant patients. My academic interests include management of BK nephropathy and CMV disease in transplant patients.
We recently implemented Allosure testing in our practice in May 2020 right in the middle of the COVID pandemic. In just 3 months, we have performed Allosure testing in almost 150 patients in our practice. I would like to share our journey and experience with all of you.
Vasil Peev, MD Rush University Medical Center
My name is Vasil Peev. I am graduate of Ruprecht- Karls University in Heidelberg, Germany. I trained to become internist and nephrologist at the University of Miami, Miller School of Medicine in Miami, Florida. I moved to Chicago following my renal fellowship and started career in transplant nephrology. I have worked as transplant nephrologist at Rush University Medical Center in Chicago, Illinois since 2014 when I joined a busy practice as part of this high volume transplant center. Here I take care of many patients either in work up or following a successful kidney transplant.
I have made very large and positive experience with Allosure which we started measuring on our transplant patients routinely since late 2017. Over the course of the last 3 years we have worked closely with CareDx and participated on their KOAR and more recently OKRA registries.
As a transplant nephrologist I am very excited to have an assay like Allosure which I can use on my renal and pancreas transplant patients. This novel assay is reliable marker of kidney "well- being" but also injury and as such can bring "peace of mind" to our patients asking providers for guidance as to how well their transplants are doing. I would like to use this opportunity to report on the performance of this remarkable novel assay.